Chromogranin A in heart failure

European Heart Journal

Volumn 23, Issue 12, 2002, Pages 926-927

  Wollert, K C ^a   Drexler, H ^a  

^a Department of Cardiology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALDOSTERONE; ANGIOTENSIN; CHROMOGRANIN A; NORADRENALIN; RENIN;

ADRENERGIC SYSTEM; CATECHOLAMINE RELEASE; EDITORIAL; HEART FAILURE; HUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

BIOLOGICAL MARKERS; CHROMOGRANIN A; CHROMOGRANINS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0036623631     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3132     Document Type: Editorial

References (17)

1. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962; 267: 650-4.
2. Braunwald E, Bristow MR. Congestive heart failure. Fifty years of progress. Circulation 2000; 102 (Suppl IV): 14-23.
3. Ceconi, C, Ferrari R, Bachetti T et al. Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002; 23: 967-74.
4. Mouland AJ, Bevan S, White JH, Hendy GN. Human chromogranin A gene. Molecular cloning, structural analysis, and neuroendocrine cell-specific expression. J Biol Chem 1994; 269: 6918-26.
5. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an on/off switch controlling dense-core secretory granule biogenesis. Cell 2001; 106: 499-509.
6. Mahata SK, O'Connor DT, Mahata M et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-33.
7. Parmer RJ, Mahata M, Gong Y et al. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J Clin Invest 2000; 106: 907-15.
8. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998; 19: 1241-8.
9. Brekke JF, Kirkeleit J, Lugardon K, Helle KB. Vasostatins. Dilators of bovine resistance arteries. Adv Exp Med Biol 2000; 482: 239-46.
10. Ratti S, Curnis F, Longhi R et al. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem 2000; 275: 29257-63.
11. Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S et al. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J Biol Chem 2001; 276: 13113-20.
12. Lugardon K, Raffner R, Goumon Y et al. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 2000; 275: 10745-53.
13. Takiyyuddin MA, Cervenka JH, Sullivan PA et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 1990; 81: 185-95.
14. Cryer PE, Wortsman J, Shah SD, Nowak RM, Deftos LJ. Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol 1991; 260: E243-6.
15. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympatho-adrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984; 311: 764-70.
16. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O'Connor DT. Chromogranin A. Storage and release in hypertension. Hypertension 1990; 15: 237-46.
17. 344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999; 274: 2920-8.